We then investigated GR/PRMT5 interactions in 442 patients with invasive BCs sampled at diagnosis including all BC subtypes; 75.9% of luminal A, 13% of luminal B, 4.6% of HER2 enriched, and 6.5% of TNBC. This evidence concerns the gene PRMT5 and breast cancer.